Antiviral agent 86

Antiviral agent 86 (Compound 2p) (5 days) potently inhibits the replication of HCoV-229E in HEL299 cells, with an EC₅₀ of 9.3 μM, and no cytotoxicity is detected at a concentration of 100 μM^[1].
Antiviral agent 86 (5 days) inhibits the replication of SARS-CoV-2 in A549ACE2/TMPRSS2 cells, with an EC₅₀ of 12 μM, and no cytotoxicity is detected at a concentration of 100 μM^[1].
Antiviral agent 86 (1-5 days) exhibits pan-coronavirus activity and acts on human and animal coronaviruses belonging to the α and β genera, with EC₉₀ values ranging from 2.2 μM (HCoV-OC43 in HRT-18G cells) to 30 μM (TGEV in ST cells). No cytotoxicity is detected at a concentration of 100 μM across all tested cell lines^[1].
Antiviral agent 86 (20 μM, 1 day) potently inhibits the production of viral dsRNA in HCoV-229E-infected 16HBE cells, indicating that it is capable of suppressing viral replication^[1].
Antiviral agent 86 (0.205-50 μM; 5 days) exhibits additive antiviral activity when used in combination with GS-441524 (HY-103586) in HCoV-229E-infected HEL299 cells^[1].
Antiviral agent 86 (5 days) shows reduced potency against nsp15 mutant (V42A or F230L) HCoV-229E in HEL299 cells, with its EC₉₀ values increasing to 7.7 μM and 9.4 μM, respectively^[1].
Antiviral agent 86 (6.25-200 μM; 120-second association, 360-second dissociation) binds directly to recombinant HCoV-229E nsp15 protein, with a K_D value of approximately 67 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.